Francine Foss MD

Dr. Francine Foss is a Professor of Medicine in the Section of Medical Oncology at Yale Cancer Center and is an internationally recognized clinician and clinical researcher with expertise in adult lymphomas and stem cell transplantation. She has developed and tested therapies that have been used to treat thousands of cancer patients, and her research has substantially impacted the field of stem cell research, benefiting patients at Yale and around the world. Dr. Foss has brought a nationally established clinical trials program to Yale Cancer Center. In her previous position at Tufts New England Medical Center in Boston, she designed, initiated, and directed multi-center national clinical trials which led to FDA approval of several novel therapies for lymphomas.

One of these, Interleukin-2- Diphtheria toxin fusion protein, was the first FDA-approved fusion protein biologic drug and the first drug to be FDA-approved for the treatment of T-cell lymphoma. In her laboratory work, she investigated and elucidated the mechanism by which extracorporeal photopheresis modulated antigen-presenting cells, leading to a reduction in graft-vs-host disease in patients undergoing allogeneic stem cell transplant. These findings led to the initiation of two National Cancer Institute-sponsored trials to confirm these results in patients with lymphoma and myelodysplastic syndrome. Dr. Foss is a member of the Stem Cell Therapy clinical program at Smilow Cancer Hospital.

Dr. Foss is a world expert in T cell Lymphomas. She has pioneered several novel therapies for T-cell lymphomas and has been a leader in many national studies. She developed and initiated the first national registry for T cell lymphomas in the United States and is a founder and co-chairman of the T CELL Forum, the preeminent international T cell lymphoma research meeting. She is a co-founder of the United States Cutaneous Lymphoma Consortium and currently serves as its President. She has been a Director of the international T-cell Project to research the treatment and biology of T-cell lymphomas and serves on the NCCN panel of experts for T-cell lymphomas.

As a translational researcher in T cell Lymphomas, she currently is collaborating with a number of laboratories and scientists at Yale to identify molecular targets in T Cell Lymphoma and recently was awarded a grant through the PITCH program for the state of Connecticut to develop a promising small molecule therapeutic for a rare form of lymphoma. Dr. Foss currently leads the multi-disciplinary T-cell Lymphoma clinical team at the Smilow Cancer Center and co-directs the Cutaneous Lymphoma Program at Yale with Dr. Michael Girardi. Her clinical practice at Smilow Cancer Hospital attracts patients from around the world.